Tilray Brands, Inc. (TLRY)
USD 0.44
(-3.84%)
USD 0.44
(-3.84%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 788.94 Million USD | 25.8% |
| 2023 | 627.12 Million USD | -0.2% |
| 2022 | 628.37 Million USD | 22.47% |
| 2021 | 513.08 Million USD | 31.23% |
| 2020 | 390.99 Million CAD | 123.11% |
| 2019 | 175.24 Million CAD | 512.12% |
| 2018 | 28.62 Million CAD | 88.71% |
| 2017 | 15.17 Million CAD | 134.62% |
| 2016 | 6.46 Million CAD | 1357.38% |
| 2015 | 443.7 Thousand CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 FY | 788.94 Million USD | 25.8% |
| 2024 Q1 | 176.94 Million USD | -3.93% |
| 2024 Q2 | 193.77 Million USD | 9.51% |
| 2024 Q3 | 188.34 Million USD | -2.8% |
| 2024 Q4 | 229.88 Million USD | 22.06% |
| 2023 Q4 | 184.18 Million USD | 26.51% |
| 2023 Q3 | 145.58 Million USD | 1.01% |
| 2023 FY | 627.12 Million USD | -0.2% |
| 2023 Q1 | 153.21 Million USD | -0.07% |
| 2023 Q2 | 144.13 Million USD | -5.92% |
| 2022 Q3 | 151.87 Million USD | -2.12% |
| 2022 Q4 | 153.32 Million USD | 0.96% |
| 2022 FY | 628.37 Million USD | 22.47% |
| 2022 Q2 | 155.15 Million USD | -7.66% |
| 2022 Q1 | 168.02 Million USD | 18.13% |
| 2021 Q4 | 142.23 Million USD | 17.97% |
| 2021 Q1 | 110.59 Million CAD | 0.79% |
| 2021 Q2 | 123.63 Million CAD | 11.79% |
| 2021 Q3 | 120.57 Million CAD | -2.48% |
| 2021 FY | 513.08 Million USD | 31.23% |
| 2020 Q3 | 107.39 Million CAD | 18.78% |
| 2020 FY | 390.99 Million CAD | 123.11% |
| 2020 Q1 | 94.35 Million CAD | 1.81% |
| 2020 Q4 | 109.72 Million CAD | 2.18% |
| 2020 Q2 | 90.41 Million CAD | -4.18% |
| 2019 Q3 | 55.96 Million CAD | 242.97% |
| 2019 Q2 | 16.31 Million CAD | 59.45% |
| 2019 Q1 | 10.23 Million CAD | 11.91% |
| 2019 FY | 175.24 Million CAD | 512.12% |
| 2019 Q4 | 92.68 Million CAD | 65.6% |
| 2018 Q1 | 4.84 Million CAD | 20.86% |
| 2018 Q3 | 8.03 Million CAD | 21.62% |
| 2018 Q4 | 9.14 Million CAD | 13.79% |
| 2018 FY | 28.62 Million CAD | 88.71% |
| 2018 Q2 | 6.6 Million CAD | 36.29% |
| 2017 Q3 | 3.88 Million CAD | -0.25% |
| 2017 Q4 | 4.01 Million CAD | 3.38% |
| 2017 FY | 15.17 Million CAD | 134.62% |
| 2017 Q1 | 3.34 Million CAD | 45.87% |
| 2017 Q2 | 3.89 Million CAD | 16.39% |
| 2016 Q1 | 717.97 Thousand CAD | 78.38% |
| 2016 FY | 6.46 Million CAD | 1357.38% |
| 2016 Q4 | 2.29 Million CAD | 15.87% |
| 2016 Q3 | 1.97 Million CAD | 30.46% |
| 2016 Q2 | 1.51 Million CAD | 111.14% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 FY | 443.7 Thousand CAD | 0.0% |
| 2015 Q4 | 402.5 Thousand CAD | 877.12% |
| 2015 Q3 | 41.19 Thousand CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -1459.698% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | -39.2% |
| Journey Medical Corporation | 79.18 Million USD | -896.378% |
| Dynavax Technologies Corporation | 232.28 Million USD | -239.645% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -578.17% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | -69.895% |
| Pacira BioSciences, Inc. | 674.97 Million USD | -16.884% |
| PainReform Ltd. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -13450.145% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -3174.598% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -3174.598% |
| SCYNEXIS, Inc. | 140.14 Million USD | -462.963% |
| Silver Spike Investment Corp. | 11.72 Million USD | -6630.362% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -40809.683% |
| Alpha Teknova, Inc. | 36.68 Million USD | -2050.643% |
| Alvotech | 91.43 Million USD | -762.854% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | -62.062% |
| Bright Green Corporation | 401.49 Thousand USD | -196403.035% |
| Embecta Corp. | 1.12 Billion USD | 29.609% |
| Safety Shot Inc | 202.67 Thousand USD | -389174.19% |
| Procaps Group, S.A. | 409.92 Million USD | -92.462% |
| Cosmos Health Inc. | 53.37 Million USD | -1378.06% |
| Theratechnologies Inc. | 81.76 Million USD | -864.901% |
| Harrow Health, Inc. | 130.19 Million USD | -505.979% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -6095.069% |
| Biofrontera Inc. | 34.07 Million USD | -2215.582% |
| DURECT Corporation | 8.54 Million USD | -9129.551% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -29.863% |
| Cronos Group Inc. | 88.84 Million USD | -788.039% |
| OptiNose, Inc. | 70.98 Million USD | -1011.389% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | -78.197% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -12013.021% |
| Organogenesis Holdings Inc. | 433.14 Million USD | -82.145% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -6341.105% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -1894.67% |
| Radius Health, Inc. | 2.88 Billion USD | 72.627% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -2341.885% |
| ProPhase Labs, Inc. | 44.38 Million USD | -1677.537% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 22.476% |
| Procaps Group S.A. | 409.92 Million USD | -92.462% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -60494.624% |
| Viatris Inc. | 15.42 Billion USD | 94.886% |
| Rockwell Medical, Inc. | 83.61 Million USD | -843.575% |
| Aytu BioPharma, Inc. | 81 Million USD | -873.978% |
| SIGA Technologies, Inc. | 139.91 Million USD | -463.863% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -515.107% |
| Shineco, Inc. | 9.8 Million USD | -7948.904% |
| PetIQ, Inc. | 1.1 Billion USD | 28.406% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -6574416.667% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 58.193% |
| Alimera Sciences, Inc. | 80.75 Million USD | -876.97% |
| Assertio Holdings, Inc. | 152.06 Million USD | -418.805% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -4429.724% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -73194.16% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -2721.378% |
| Hempacco Co., Inc. | 4.04 Million USD | -19401.058% |
| Talphera, Inc. | 651 Thousand USD | -121089.247% |
| Alvotech | 91.43 Million USD | -762.854% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | -149.184% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 39.145% |
| Currenc Group, Inc. | 53.25 Million USD | -1381.432% |
| Kamada Ltd. | 144.75 Million USD | -445.005% |
| Indivior PLC | 1.09 Billion USD | 27.819% |
| Evoke Pharma, Inc. | 5.18 Million USD | -15128.688% |
| Flora Growth Corp. | 76.07 Million USD | -937.113% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -73194.16% |
| Evolus, Inc. | 202.08 Million USD | -290.401% |
| HUTCHMED (China) Limited | 837.99 Million USD | 5.854% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | -22.431% |
| Akanda Corp. | 2.16 Million USD | -36424.213% |